valganciclovir


Also found in: Acronyms, Wikipedia.

valganciclovir

 [val″gan-si´klo-vir]
a prodrug of ganciclovir, used in treatment of cytomegalovirus infections in immunocompromised patients; administered orally as the hydrochloride salt.

valganciclovir

/val·gan·ci·clo·vir/ (val″gan-si´klo-vir) a prodrug of ganciclovir, used as the hydrochloride salt in the treatment of cytomegalovirus retinitis in patients with AIDS.

valganciclovir

[val′gan-si′klo-vir]
a prodrug of ganciclovir, used in treatment of cytomegalovirus infections in immunocompromised patients and administered orally as the hydrochloride salt.

valganciclovir

A pro-drug of GANCICLOVIR used to treat CYTOMEGALOVIRUS INFECTION especially with retinitis. A brand name is Valcyte.
References in periodicals archive ?
Survival in patients with glioblastoma receiving valganciclovir.
Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
Although the longer treatment with valganciclovir was expensive, the cost was largely offset by reducing the number of patients who contracted CMV disease, which in turn averted its long-term adverse consequences.
Durante los diez dias siguientes se mantuvo afebril por lo que siguio control en la consulta de trasplantes y acudio a ponerse el tratamiento de forma ambulatoria hasta finalizar pauta intravenosa y pasar a valganciclovir oral.
Anti-CMV therapy exists in various forms (intravenous, oral and intravitreal) and includes ganciclovir, valganciclovir, foscarnet and cidofovir.
The study's results suggest that valganciclovir may be an effective and safe way to both prevent and treat these HHV-8-related diseases, he said at the annual meeting of the Infectious Diseases Society of America.
In a double-blind clinical trial of valganciclovir involving 42 patients with glioblastoma, an exploratory analysis of 22 patients receiving at least six months of antiviral therapy showed 50% overall survival at two years compared with 20.
CMV has been called the 'neglected disease of the AIDS pandemic', in part because of limited access to treatment, especially in the developing world, where localised intra-ocular ganciclovir implants and systemic oral valganciclovir are unavailable or too costly.
Treatment was changed to oral valganciclovir, 900 mg 2x/d for 20 days, upon discharge.
The drug valganciclovir can eradicate active CMV infection.
TREATMENT: THE URGENT NEED FOR VALGANCICLOVIR PRICE REDUCTION IN SA FOR CMV TREATMENT IN HIV PATIENTS